405 related articles for article (PubMed ID: 21487112)
1. New markers for minimal residual disease detection in acute lymphoblastic leukemia.
Coustan-Smith E; Song G; Clark C; Key L; Liu P; Mehrpooya M; Stow P; Su X; Shurtleff S; Pui CH; Downing JR; Campana D
Blood; 2011 Jun; 117(23):6267-76. PubMed ID: 21487112
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
[TBL] [Abstract][Full Text] [Related]
3. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of CD73, CD86 and CD304 in normal vs. leukemic B-cell precursors and their utility as stable minimal residual disease markers in childhood B-cell precursor acute lymphoblastic leukemia.
Sędek Ł; Theunissen P; Sobral da Costa E; van der Sluijs-Gelling A; Mejstrikova E; Gaipa G; Sonsala A; Twardoch M; Oliveira E; Novakova M; Buracchi C; van Dongen JJM; Orfao A; van der Velden VHJ; Szczepański T;
J Immunol Methods; 2019 Dec; 475():112429. PubMed ID: 29530508
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
DiGiuseppe JA; Fuller SG; Borowitz MJ
Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
[TBL] [Abstract][Full Text] [Related]
6. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract][Full Text] [Related]
7. High frequency of heat shock protein 27 overexpression is a highly effective, high-coverage marker for minimal residual disease detection in children with B-cell acute lymphoblastic leukemia.
Chou SW; Su YH; Lu MY; Chang HH; Yang YL; Lin DT; Lin KH; Coustan-Smith E; Jou ST
Pediatr Blood Cancer; 2023 Jan; 70(1):e29990. PubMed ID: 36250996
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia.
Chen JS; Coustan-Smith E; Suzuki T; Neale GA; Mihara K; Pui CH; Campana D
Blood; 2001 Apr; 97(7):2115-20. PubMed ID: 11264179
[TBL] [Abstract][Full Text] [Related]
9. Neuropilin-1/CD304 Expression by Flow Cytometry in Pediatric Precursor B-Acute Lymphoblastic Leukemia: A Minimal Residual Disease and Potential Prognostic Marker.
Abaza HM; Alfeky MAA; Eissa DS; Abdel Fattah MF; Annaka LM; Ebeid FS
J Pediatr Hematol Oncol; 2018 Apr; 40(3):200-207. PubMed ID: 29200164
[TBL] [Abstract][Full Text] [Related]
10. Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
Chowdhury S; Bandyopadhyay S; Mandal C; Chandra S; Mandal C
BMC Cancer; 2008 Feb; 8():40. PubMed ID: 18241334
[TBL] [Abstract][Full Text] [Related]
11. CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.
Dworzak MN; Fröschl G; Printz D; Zen LD; Gaipa G; Ratei R; Basso G; Biondi A; Ludwig WD; Gadner H
Leukemia; 2004 Apr; 18(4):703-8. PubMed ID: 14961034
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of detecting minimal residual disease in acute childhood B-cell lymphoblastic leukemia with flow cytometry].
Zhang LP; Cheng YF; Liu GL; Lu AD; Liu YR; Wang H
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):481-5. PubMed ID: 16083543
[TBL] [Abstract][Full Text] [Related]
13. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
Baraka A; Sherief LM; Kamal NM; Shorbagy SE
Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
[TBL] [Abstract][Full Text] [Related]
14. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
[TBL] [Abstract][Full Text] [Related]
15. CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.
Solly F; Angelot F; Garand R; Ferrand C; Seillès E; Schillinger F; Decobecq A; Billot M; Larosa F; Plouvier E; Deconinck E; Legrand F; Saas P; Rohrlich PS; Garnache-Ottou F
Cytometry A; 2012 Jan; 81(1):17-24. PubMed ID: 22052678
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
[TBL] [Abstract][Full Text] [Related]
17. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
[TBL] [Abstract][Full Text] [Related]
18. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
[TBL] [Abstract][Full Text] [Related]
19. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia.
Gaipa G; Basso G; Biondi A; Campana D
Cytometry B Clin Cytom; 2013; 84(6):359-69. PubMed ID: 23757107
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]